Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5-mg once-daily dosage regimen
- 25 August 2006
- journal article
- research article
- Published by Springer Nature in Journal of Bone and Mineral Metabolism
- Vol. 24 (5) , 405-413
Abstract
In this multicenter, randomized, double-blind controlled trial, the efficacy and safety of once-weekly dosing with 17.5 mg risedronate was compared with once-daily dosing with 2.5 mg risedronate in Japanese patients with involutional osteoporosis. A total of 496 patients were randomized to receive either once-weekly (n = 249) or once-daily (n = 247) treatment. All patients were supplemented with 200 mg/day calcium. Following 48 weeks of treatment, the mean (±SD) percent changes, from baseline, in the bone mineral density of the lumbar spine (L2-L4 BMD) in the once-weekly and once-daily treatment groups were 5.36 ± 4.27% and 5.87 ± 4.47%, respectively. The difference between the groups was −0.5% (95% confidence interval: −1.35% to 0.35%), demonstrating that the effect on BMD of once-weekly treatment was not inferior to that of once-daily treatment. The time-course reductions in biochemical markers of bone resorption (urinary N- and C-telopeptide of type I collagen) and bone formation (bone-specific alkaline phosphatase) were similar for the two dosing regimens. There were no differences in the incidence of new vertebral fractures or the worsening of existing fractures between the once-weekly (2.2%) and once-daily (2.7%) dosing regimens. No significant differences were observed between the two dosing regimens in the incidence or the type of adverse events. However, 10.1% of the patients in the once-daily group withdrew due to adverse events as compared to 5.2% in the once-weekly group. Moreover, drug-related adverse events, including upper gastrointestinal disorders and abnormal changes in laboratory parameters, tended to be less in the once-weekly dosing regimen than in the once-daily dosing regimen. In conclusion, once-weekly oral dosing with 17.5 mg risedronate was well tolerated in Japanese osteoporotic patients, and showed equivalent efficacy to once-daily oral dosing with 2.5 mg risedronate. This once-weekly regimen is expected to provide a more convenient therapeutic option as an alternative to daily dosing and to enhance patient compliance in long-term therapy for osteoporosis.Keywords
This publication has 26 references indexed in Scilit:
- A comparison of incidences of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and etidronate: a randomized, double-masked trialJournal of Bone and Mineral Metabolism, 2004
- Clinical trial of risedronate in Japanese volunteers: single and multiple oral dose studiesJournal of Bone and Mineral Metabolism, 2004
- Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With RisedronateJournal of Bone and Mineral Research, 2003
- Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience☆☆This study was sponsored by Procter & Gamble Pharmaceuticals, Cincinnati, Ohio, and Aventis Pharma, Bridgewater, New Jersey.Bone, 2003
- Two-Year Results of Once-Weekly Administration of Alendronate 70 mg for the Treatment of Postmenopausal OsteoporosisJournal of Bone and Mineral Research, 2002
- Effect of Risedronate on the Risk of Hip Fracture in Elderly WomenNew England Journal of Medicine, 2001
- Dose‐Proportional Pharmacokinetics of Risedronate on Single‐Dose Oral Administration to Healthy VolunteersThe Journal of Clinical Pharmacology, 2000
- Bisphosphonates: A review of their pharmacokinetic propertiesBone, 1996
- The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in ratsJournal of Bone and Mineral Research, 1991
- Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone diseaseBone and Mineral, 1990